INDUSTRY NEWS
SECTION TITLE
Patheon Names New Senior Vice President for Small Molecule API Business
Patheon, a global provider of pharmaceutical development and manufacturing services, announced that Patrick Glaser was appointed senior vice president of the company’s small molecule active pharmaceutical ingredient (API) business. He will be responsible for leading the transformation and expansion of the company’s API service offering in Europe and North America and will report to Lukas Utiger, president of Patheon’s drug substance services division.
Glaser joins Patheon from Teva Pharmaceutical Industries where he served as vice president of sales and marketing, API, North America and had business responsibility for more than 300 APIs. He previously held senior management, strategic marketing and business development positions at Novasep Groupe where he was president and CEO. Glaser had global responsibility for three business units: synthesis, biopharma and industrial biotech, and also managed the divestiture of non-core Novasep businesses.
“Patrick brings more than 20 years of leadership experience in the pharmaceutical industry,” said Utiger. ”We will benefit from his depth of knowledge of the industry and expertise in strategic business development as we work to continue expanding our API business.”
Glaser earned a bachelor of arts in economics from Fairleigh Dickinson University in Madison, NJ. He previously was a member of the board of directors of the Drug Chemical and Associated Technologies Association (DCAT).
Emergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9M to Develop and Manufacture a Zika Vaccine
Emergent BioSolutions has announced that its Center for Innovation in Advanced Developmentand Manufacturing (CIADM) has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $21.9 million to develop and manufacture three cGMP lots of a Zika vaccine for use in a Phase 1 clinical trial. Using a base vaccine candidate provided by BARDA, the company will conduct technology transfer of process materials and information, process and analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance and final drug product. The task order consists of a 30-month base valued at $17.9 million and includes options that, if executed, will bring the total value to up to $21.9 million.
“Emergent is pleased to partner with BARDA to address the emerging public health threat in Zika,” said Adam Havey, executive vice president and president, biodefense division of Emergent BioSolutions. “We look forward to executing on this task order and working collaboratively with the government in its efforts to help contain this epidemic.”
This is the first Zika-related BARDA Task Order awarded to Emergent under the CIADM program. In 2012, Emergent was designated by the U.S. Department of Health and Human Services (HHS) as a CIADM, which allows the company to contract with the U.S. government through task order requests for requirements such as operational readiness, development and manufacturing of CBRN products, warm base maintenance, surge manufacturing, and workforce development.
This Task Order Number HHSO10033003T under contract HHSO100201200004I is funded by BARDA, within the Office of the Assistant Secretary for Preparedness and Response in HHS.
Sharp Packaging Solutions Invests $45 M to Increase Contract Packaging Capabilities By 30%
Sharp Packaging Solutions has increased its packaging capacity by 30% for its life science customers with a $45 million investment in a new Center of Excellence for specialty/biologic/cold chain packaging on Penn Am Drive, Allentown and in the addition of four new bottling lines within its adjacent 270,000 square foot contract packaging facilities at 7451 and 7529 Keebler Way. The Center of Excellence marks Sharp’s third expansion within the Allentown campus since 2014. The contract packaging building at 7529 Keebler Way opened in 2014 and houses six packaging suites, and a technical warehouse and office suite facility opened in 2014 at 7350 William Avenue.
Sharp seized the opportunity to purchase the 112,000 square foot Penn Am Drive building in 2014, and began interior demolition and construction to offer a state-of-the-art biologic and specialty product packaging operation, complete with comprehensive cold chain and serialization capabilities. After internal construction was completed earlier this year, Sharp moved the company’s existing specialty and biologic packaging lines from its Keebler Way plant to the new Center. It then installed 2 to 8° Celsius cold storage to house 600 pallets, doubling its total refrigeration capacity, and invested in additional packaging and serialization equipment. The investment in this new facility substantially increases Sharp’s ability to handle specialty packaging requirements, with room to increase capacity for these products an additional 30%. Qualification and commissioning of the Center of Excellence was completed in April, 2016, and Sharp commenced commercial packaging activities in June.
By consolidating all its specialty and biologic equipment in the new Center of Excellence, Sharp will open up additional packaging capacity for bottling at its Keebler Way facility by September 2016. All bottling lines will be serialization ready, as well as all lines in the Center of Excellence, well in advance of industry requirements for meeting track and trace regulations by 2017. An industry pioneer in serialization, Sharp has been providing serialization services to clients since 2008, with over two billion units serialized in six different formats for 35 client programs, from bottle and individual blister to pallets in support of seven international programs. With the addition of the new capabilities
pharmoutsourcing.com | 47 | July/August 2016
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54